Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin American Newswire.
Press releases published on September 11, 2025
Hesai Group Announces Pricing of Global Offering
GlobeNewswire
·
September 11, 2025
SHANGHAI, China, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Hesai Group (NASDAQ: HSAI) (“Hesai” or the “Company”), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced the pricing of its global offering (the “Global …
OnRe Launches Points Program: Turn Your DeFi Activity into Rewards
GlobeNewswire
·
September 11, 2025
Hamilton, Bermuda, Sept. 11, 2025 (GLOBE NEWSWIRE) -- OnRe, the onchain asset manager delivering institutional-grade yield to DeFi, today launched OnRe Points, a rewards program designed to incentivize meaningful participation in the ONyc ecosystem. Unlike …
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
GlobeNewswire
·
September 11, 2025
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design confirmatory trial planned for 2026 FORT …
Update on the Increasing Value in Globex
GlobeNewswire
·
September 11, 2025
TORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang …
Rio Silver arranges $1.3M private placement
GlobeNewswire
·
September 11, 2025
VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – September 11, 2025 – Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX.V: RYO) (OTC: RYOOF) announces private placement of units. Rio Silver Inc. has arranged …
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
September 11, 2025
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs …
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
GlobeNewswire
·
September 11, 2025
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug- …
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
GlobeNewswire
·
September 11, 2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
GlobeNewswire
·
September 11, 2025
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Sky Pharm SA, signed a …
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
GlobeNewswire
·
September 11, 2025
BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal’s sodium oxybate oral solution 500 mg/mL Abbreviated New Drug …
CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical
GlobeNewswire
·
September 11, 2025
LAS VEGAS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the receipt of an …
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
GlobeNewswire
·
September 11, 2025
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 …
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
GlobeNewswire
·
September 11, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today …
HPQ Awarded Up to $3M in Federal Funding to Fast-Track Commercialization of Silicon-Based Battery Materials
GlobeNewswire
·
September 11, 2025
MONTREAL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a Quebec-based technology company driving innovation in advanced materials and critical process development, is pleased to announce …
HPQ obtient jusqu’à 3 M$ en financement du gouvernement fédérales pour accélérer la commercialisation de matériaux de batteries à base de silicium
GlobeNewswire
·
September 11, 2025
MONTRÉAL, 11 sept. 2025 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), une entreprise technologique québécoise spécialisée dans l’innovation en matériaux avancés et le développement de procédés …
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
GlobeNewswire
·
September 11, 2025
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, …
Pasinex Consolidates 100% Ownership of Horzum A.Ş.
GlobeNewswire
·
September 11, 2025
TORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE; FSE: PNX) (“Pasinex” or the “Company”) today announced it has executed a Share Transfer and Settlement Agreement (the “Agreement”) with Kurmel Holding A.S., Akmetal Dis …
Tecnoglass Announces Third Quarter 2025 Dividend
GlobeNewswire
·
September 11, 2025
Miami, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today …
OR Royalties Announces More Positive Developments on Select Assets
GlobeNewswire
·
September 11, 2025
MONTRÉAL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX …
Redevances OR annonce des développements positifs sur des actifs clés
GlobeNewswire
·
September 11, 2025
MONTRÉAL, 11 sept. 2025 (GLOBE NEWSWIRE) -- Redevances OR Inc. (« Redevances OR » ou la « Société ») (TSX et NYSE : OR) a le plaisir de fournir les mises à jour suivantes concernant certains actifs. Les montants sont exprimés en dollars américains, sauf …